Refine your search
-
Authors
-
Item types
-
Topics
- *Alemtuzumab/tu [Therapeutic Use]
- *Fasciitis, Necrotizing/et [Etiology]
- *Immunologic Factors/ae [Adverse Effects]
- *Interferon beta-1a/ae [Adverse Effects]
- *Multiple Sclerosis, Relapsing-Remitting/dt [Drug Therapy]
- *Shock, Septic/et [Etiology]
- Alemtuzumab/ae [Adverse Effects]
- Alemtuzumab/pk [Pharmacokinetics]
- CD52 Antigen/im [Immunology]
- Clinical Trials as Topic
- Debridement
- Fasciitis, Necrotizing/su [Surgery]
- Half-Life
- Humans
- Immunologic Factors/ad [Administration & Dosage]
- Injections, Intramuscular/ae [Adverse Effects]
- Interferon beta-1a/ad [Administration & Dosage]
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Show more
- Show less
-
Collections
-
Languages